Valuation: Veloxis Pharmaceuticals A/S

Market Cap 10.46B 71B 9.5B 8.78B 7.93B 14.96B 982B 15.49B 106B 41.82B 527B 39.23B 38.4B 1,669B P/E 2017
-154x
P/E 2018 -708x
Enterprise Value 10.49B 71.2B 9.53B 8.8B 7.95B 15B 985B 15.53B 106B 41.94B 528B 39.34B 38.51B 1,674B EV / Sales 2017
49.4x
EV / Sales 2018 95.8x
Free-Float
10%
Yield 2017 *
-
Yield 2018 -
30/05/24 Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia CI
28/06/22 Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) CI
26/04/21 Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA. CI
17/02/20 Veloxis Pharmaceuticals A/S Announces Board Appointments CI
07/02/20 Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index CI
30/01/20 Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index CI
30/01/20 Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index CI
14/01/20 Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others. CI
25/11/19 Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
25/11/19 Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion. CI
13/11/19 Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
12/11/19 Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
31/10/19 Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019 CI
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 13/09/2017
Chief Operating Officer - 01/03/2016
Director TitleAgeSince
Chairman - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.64B
-0.82%+5.74%+39.64%+143.26% 1,286B
-1.12%+2.29%+44.21%+89.89% 688B
-0.16%+1.11%+26.76%+114.06% 521B
+1.14%+4.87%+43.06%+71.97% 386B
-2.23%-1.55%+55.47%+42.54% 364B
+1.27%+2.01%+30.01%+62.35% 302B
+0.37%+0.75%+3.71%+39.09% 287B
-0.72%+0.41%+37.29%+69.33% 252B
-0.30%+0.41%+34.04%+123.32% 208B
Average -0.26%+1.87%+34.91%+83.98% 430B
Weighted average by Cap. -0.47%+3.25%+36.97%+98.27%

Financials

2017 2018
Net sales 30.17M 205M 27.41M 25.32M 22.87M 43.17M 2.83B 44.68M 305M 121M 1.52B 113M 111M 4.81B 39.49M 268M 35.88M 33.15M 29.94M 56.51M 3.71B 58.5M 399M 158M 1.99B 148M 145M 6.3B
Net income -9.54M -64.79M -8.67M -8.01M -7.23M -13.65M -896M -14.13M -96.32M -38.17M -481M -35.81M -35.05M -1.52B -5.28M -35.89M -4.8M -4.44M -4.01M -7.56M -496M -7.83M -53.35M -21.14M -266M -19.83M -19.41M -844M
Net Debt 18.05M 123M 16.4M 15.15M 13.69M 25.83M 1.7B 26.74M 182M 72.2M 910M 67.74M 66.3M 2.88B 29.38M 200M 26.7M 24.67M 22.28M 42.05M 2.76B 43.53M 297M 118M 1.48B 110M 108M 4.69B
Logo Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Company’s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Company’s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.
Employees
-
  1. Stock Market
  2. Stocks
  3. VELO Stock